We are excited to announce the launch of a new phase in our Alzheimer’s research: the start of blood-based studies focusing on the RNA modification N¹-methyladenosine (m¹A).

Having already identified m¹A as a potential early marker of mitochondrial dysfunction in the brain, we are now extending our investigations to blood samples, a key step toward developing non-invasive biomarkers for early detection.

This work is conducted in collaboration with the Department of Psychiatry at the University Medical Center Mainz, helping to bridge molecular research and clinical application.

Our goal: to better understand the molecular changes behind Alzheimer’s—and bring that knowledge closer to the clinic.